Developer docs
API playgroundTry for free, no card

Search company profiles

Buzzard Pharmaceuticals AB

Full company profile

uuid00276tj

Namestring
Buzzard Pharmaceuticals AB
Legal namestring
Buzzard Pharmaceuticals AB
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Buzzard Pharmaceuticals AB is a clinical-stage Swedish biotech company founded in 2016 and headquartered in Stockholm/Solna, Sweden, developing a single asset — isunakinra (EBI-005) — a next-generation IL-1 receptor (IL1R1) inhibitor designed as a chimeric protein that blocks both IL-1α and IL-1β with up to 20x the potency of endogenous IL-1Ra, no agonistic activity, and thermal stability. The drug is being developed in oncology indications where chronic inflammation drives tumor immune evasion, with active clinical work in microsatellite-stable, KRAS-mutated colorectal cancer and a planned study in neoadjuvant triple-negative breast cancer (TNBC), both as monotherapy and in combination with PD-1 checkpoint inhibitors.

The company is prosecuting its Phase 1/2a trial under an active US IND in collaboration with Dr. Carlos Becerra at Baylor University in Dallas, TX, with trial NCT06634875 publicly disclosed. The Phase 1 dose escalation read-out was described as promising, and the company cites preclinical synergy between isunakinra and PD-1 inhibitors and best-in-class preclinical efficacy in KRAS-mutated tumors as the mechanistic rationale. The team is led by CEO & Co-founder Maarten de Château (former CEO of Cormorant Pharmaceuticals, acquired by Bristol Myers Squibb), with CMO Chris Nowak and CSO Hans Olivecrona (CMO of Buzzard since 2017), supported by a board chaired by Urban Paulsson and including Carl-Johan Spak and Mattias Häggblom (Sector Head of Healthcare Equity Research at Handelsbanken).

Buzzard's business model is pre-revenue and partner-oriented: there is no commercial product, no pricing, and no disclosed licensing income in the input; the company employs 1–10 people, expects revenue only upon regulatory approval, and frames future commercialization as targeting pharmaceutical/biotech partners or a direct commercial launch post-approval. As a one-asset, single-indication-axis clinical biotech with no disclosed funding rounds, its commercial trajectory is dependent on continued clinical read-outs, an indication expansion into TNBC, and ultimately a BD transaction or commercial launch.

Short descriptiontext

Buzzard Pharmaceuticals AB is a clinical-stage Swedish biotech developing isunakinra (EBI-005), a dual IL-1α/IL-1β receptor antagonist in Phase 1/2a trials for KRAS-mutated colorectal cancer and planned triple-negative breast cancer.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSolna, Sweden
HQ citystring
Solna
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
IL-1 inhibitor therapy, cancer immunotherapy, clinical stage biotech, checkpoint inhibitor combination, solid tumor treatment
Industry3 codes
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Oncology Biopharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Development
TypeOne Time License
Description

Pre-revenue clinical-stage biotech company developing isunakinra for cancer indications. Revenue will be generated upon regulatory approval and commercialization of the drug candidate.

buzzardpharma.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Buzzard Pharmaceuticals AB is a clinical-stage biotech company developing Isunakinra (EBI-005), a proprietary next-generation IL-1 inhibitor designed to block both IL-1α and IL-1β with high potency (up to 20x IL-1Ra). The drug candidate is being evaluated in a Phase 1/2a clinical trial in solid tumors, including KRAS-mutated microsatellite stable colorectal cancer and a planned study in neoadjuvant triple-negative breast cancer, both as monotherapy and in combination with PD-1 checkpoint inhibitors.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • High potency: up to 20x IL-1Ra
+2 more records
Product overview1 text field

Buzzard Pharmaceuticals AB is a clinical-stage biotech company developing a single drug candidate, Isunakinra (EBI-005), as a next-generation IL-1 inhibitor for oncology. The drug is a potent IL-1R1 inhibitor that blocks both IL-1α and IL-1β and is being tested in a Phase 1/2a clinical trial as monotherapy and in combination with PD-1 inhibitors for solid tumors including KRAS-mutated colorectal cancer and triple-negative breast cancer.

Product and service1 record
1Isunakinra (EBI-005)
CategoryOncology Biopharmaceutical - IL-1 Inhibitor
Description

Isunakinra is a proprietary next-generation IL-1 inhibitor designed to block both IL-1α and IL-1β with high potency (up to 20x IL-1Ra), being developed as monotherapy and in combination with PD-1 checkpoint inhibitors for solid tumors including KRAS-mutated microsatellite stable colorectal cancer and triple-negative breast cancer.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical trial collaboration with Dr. Carlos Becerra at Baylor University, Dallas, TX. Study conducted under an IND for the Phase I/IIa trial of isunakinra in solid tumor patients.

2Cormorant Pharmaceuticals (acquired by Bristol Myers Squibb)
Strategic tierMinorTypeOthers
Description

Cormorant Pharmaceuticals was built and led by CEO Maarten de Château and was successfully acquired by Bristol Myers Squibb, demonstrating the ability to create significant value and deliver clinically attractive assets. This represents the CEO's prior entrepreneurial exit, not an active partnership.

buzzardpharma.com
Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
1Innate Pharma SA
TypeBroad incumbent
Description

French clinical-stage immuno-oncology company developing antibodies that modulate the tumor microenvironment, including combinations with checkpoint inhibitors. Adjacent comparable for IL-1/TME-reprogramming combination strategies in solid tumors.

TypeDirect peer
Description

Swedish clinical-stage biotech developing nadunolimab (anti-IL1RAP) for pancreatic cancer and other solid tumors. Most direct European comparable: also targets the IL-1 axis in oncology, with monotherapy and combination-IO strategies.

TypeDirect peer
Description

Clinical-stage biotech developing bermekimab (anti-IL-1α monoclonal antibody) for oncology and inflammatory indications. Direct competitor in the IL-1 oncology space with a related but distinct molecular approach (single-target antibody vs. chimeric decoy).

TypeEmerging player
Description

Clinical-stage immuno-oncology biotech developing computationally-discovered combination immunotherapy candidates. Comparable as a smaller biotech building clinical evidence for novel immuno-oncology combinations.

TypeBroad incumbent
Description

Developer of canakinumab (Ilaris), a marketed anti-IL-1β antibody, and sponsor of the CANTOS and CANOPY oncology programs. Broad incumbent that has shaped the IL-1 oncology clinical landscape against which Buzzard's isunakinra must differentiate.

TypeEmerging player
Description

Clinical-stage immuno-oncology biotech developing tumor microenvironment-modulating biologics. Comparable as a US-listed small-cap biotech pursuing conditional activation of immune pathways in solid tumors.

TypeBroad incumbent
Description

Specialty/rare-disease pharma with established rights to several IL-1-related products and a long-tenured relationship with Buzzard's leadership (CEO and CMO prior roles). Relevant comparable as both a potential commercial partner and as an investor/strategic.

TypeBroad incumbent
Description

Developer of anakinra (Kineret), the recombinant IL-1Ra upon which isunakinra is mechanistically built. Large incumbent in IL-1 biology with deep immuno-oncology pipeline, relevant as both a potential competitor and a strategic acquirer.

TypeEmerging player
Description

Clinical-stage immuno-oncology biotech developing antibody combinations with checkpoint inhibitors (e.g., sotigalimab + nivolumab). Comparable as a smaller biotech pursuing IO-combination strategies in solid tumors.

TypeEmerging player
Description

Clinical-stage oncology biotech developing Conditionally Active Biologics, including TME-modulating antibodies. Comparable as a smaller US-listed biotech developing novel biologic approaches to solid tumors.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Buzzard Pharmaceuticals AB

Oncology Biopharmaceuticalsbuzzardpharma.com

Buzzard Pharmaceuticals AB is a clinical-stage Swedish biotech developing isunakinra (EBI-005), a dual IL-1α/IL-1β receptor antagonist in Phase 1/2a trials for KRAS-mutated colorectal cancer and planned triple-negative breast cancer.

What Buzzard Pharmaceuticals AB does

Buzzard Pharmaceuticals AB is a clinical-stage Swedish biotech company founded in 2016 and headquartered in Stockholm/Solna, Sweden, developing a single asset — isunakinra (EBI-005) — a next-generation IL-1 receptor (IL1R1) inhibitor designed as a chimeric protein that blocks both IL-1α and IL-1β with up to 20x the potency of endogenous IL-1Ra, no agonistic activity, and thermal stability. The drug is being developed in oncology indications where chronic inflammation drives tumor immune evasion, with active clinical work in microsatellite-stable, KRAS-mutated colorectal cancer and a planned study in neoadjuvant triple-negative breast cancer (TNBC), both as monotherapy and in combination with PD-1 checkpoint inhibitors.

The company is prosecuting its Phase 1/2a trial under an active US IND in collaboration with Dr. Carlos Becerra at Baylor University in Dallas, TX, with trial NCT06634875 publicly disclosed. The Phase 1 dose escalation read-out was described as promising, and the company cites preclinical synergy between isunakinra and PD-1 inhibitors and best-in-class preclinical efficacy in KRAS-mutated tumors as the mechanistic rationale. The team is led by CEO & Co-founder Maarten de Château (former CEO of Cormorant Pharmaceuticals, acquired by Bristol Myers Squibb), with CMO Chris Nowak and CSO Hans Olivecrona (CMO of Buzzard since 2017), supported by a board chaired by Urban Paulsson and including Carl-Johan Spak and Mattias Häggblom (Sector Head of Healthcare Equity Research at Handelsbanken).

Buzzard's business model is pre-revenue and partner-oriented: there is no commercial product, no pricing, and no disclosed licensing income in the input; the company employs 1–10 people, expects revenue only upon regulatory approval, and frames future commercialization as targeting pharmaceutical/biotech partners or a direct commercial launch post-approval. As a one-asset, single-indication-axis clinical biotech with no disclosed funding rounds, its commercial trajectory is dependent on continued clinical read-outs, an indication expansion into TNBC, and ultimately a BD transaction or commercial launch.

Buzzard Pharmaceuticals AB firmographics

Firmographics
Name
Buzzard Pharmaceuticals AB
Legal name
Buzzard Pharmaceuticals AB
Website
https://buzzardpharma.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
1–10 employees
Short description
Buzzard Pharmaceuticals AB is a clinical-stage Swedish biotech developing isunakinra (EBI-005), a dual IL-1α/IL-1β receptor antagonist in Phase 1/2a trials for KRAS-mutated colorectal cancer and planned triple-negative breast cancer.
Ownership category
akta.pro rank

Buzzard Pharmaceuticals AB industry classification

Industry
Product category
Oncology Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • IL-1 inhibitor therapy
  • Cancer immunotherapy
  • Clinical stage biotech
  • Checkpoint inhibitor combination
  • Solid tumor treatment

Where Buzzard Pharmaceuticals AB is headquartered

Location

Headquarters

HQ city
Solna
HQ country
Sweden
HQ region
Europe

Offices1 record

Markets served

Buzzard Pharmaceuticals AB business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Development: Pre-revenue clinical-stage biotech company developing isunakinra for cancer indications. Revenue will be generated upon regulatory approval and commercialization of the drug candidate.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Buzzard Pharmaceuticals AB product offering

Product offering

Core offering

Buzzard Pharmaceuticals AB is a clinical-stage biotech company developing Isunakinra (EBI-005), a proprietary next-generation IL-1 inhibitor designed to block both IL-1α and IL-1β with high potency (up to 20x IL-1Ra). The drug candidate is being evaluated in a Phase 1/2a clinical trial in solid tumors, including KRAS-mutated microsatellite stable colorectal cancer and a planned study in neoadjuvant triple-negative breast cancer, both as monotherapy and in combination with PD-1 checkpoint inhibitors.

Product overview

Buzzard Pharmaceuticals AB is a clinical-stage biotech company developing a single drug candidate, Isunakinra (EBI-005), as a next-generation IL-1 inhibitor for oncology. The drug is a potent IL-1R1 inhibitor that blocks both IL-1α and IL-1β and is being tested in a Phase 1/2a clinical trial as monotherapy and in combination with PD-1 inhibitors for solid tumors including KRAS-mutated colorectal cancer and triple-negative breast cancer.

Differentiator

Problem solved

Functional benefit

Products and services

  • Isunakinra (EBI-005) Isunakinra is a proprietary next-generation IL-1 inhibitor designed to block both IL-1α and IL-1β with high potency (up to 20x IL-1Ra), being developed as monotherapy and in combination with PD-1 checkpoint inhibitors for solid tumors including KRAS-mutated microsatellite stable colorectal cancer and triple-negative breast cancer.

Quantifiable outcome

  • High potency: up to 20x IL-1Ra
  • +2 more outcomes

Companies that use Buzzard Pharmaceuticals AB

Customer profile

Segments2 records

Ideal customer profiles1 record

Buzzard Pharmaceuticals AB technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Buzzard Pharmaceuticals AB partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and minor.

  • Baylor University (Dr. Carlos Becerra)coreStrategic or Co-development PartnerClinical trial collaboration with Dr. Carlos Becerra at Baylor University, Dallas, TX. Study conducted under an IND for the Phase I/IIa trial of isunakinra in solid tumor patients.
  • Cormorant Pharmaceuticals (acquired by Bristol Myers Squibb)minorOthersCormorant Pharmaceuticals was built and led by CEO Maarten de Château and was successfully acquired by Bristol Myers Squibb, demonstrating the ability to create significant value and deliver clinically attractive assets. This represents the CEO's prior entrepreneurial exit, not an active partnership.

Scale indicators3 records

Recent moves4 records

Expansion highlights4 records

Buzzard Pharmaceuticals AB competitors and assessment

Company assessment

Broad incumbents

  • Innate Pharma SA: French clinical-stage immuno-oncology company developing antibodies that modulate the tumor microenvironment, including combinations with checkpoint inhibitors. Adjacent comparable for IL-1/TME-reprogramming combination strategies in solid tumors.
  • Novartis AG: Developer of canakinumab (Ilaris), a marketed anti-IL-1β antibody, and sponsor of the CANTOS and CANOPY oncology programs. Broad incumbent that has shaped the IL-1 oncology clinical landscape against which Buzzard's isunakinra must differentiate.
  • Swedish Orphan Biovitrum (Sobi): Specialty/rare-disease pharma with established rights to several IL-1-related products and a long-tenured relationship with Buzzard's leadership (CEO and CMO prior roles). Relevant comparable as both a potential commercial partner and as an investor/strategic.
  • Regeneron Pharmaceuticals: Developer of anakinra (Kineret), the recombinant IL-1Ra upon which isunakinra is mechanistically built. Large incumbent in IL-1 biology with deep immuno-oncology pipeline, relevant as both a potential competitor and a strategic acquirer.

Direct peers

  • Cantargia AB: Swedish clinical-stage biotech developing nadunolimab (anti-IL1RAP) for pancreatic cancer and other solid tumors. Most direct European comparable: also targets the IL-1 axis in oncology, with monotherapy and combination-IO strategies.
  • XBiotech Inc. Clinical-stage biotech developing bermekimab (anti-IL-1α monoclonal antibody) for oncology and inflammatory indications. Direct competitor in the IL-1 oncology space with a related but distinct molecular approach (single-target antibody vs. chimeric decoy).

Emerging players

  • Compugen Ltd. Clinical-stage immuno-oncology biotech developing computationally-discovered combination immunotherapy candidates. Comparable as a smaller biotech building clinical evidence for novel immuno-oncology combinations.
  • Werewolf Therapeutics: Clinical-stage immuno-oncology biotech developing tumor microenvironment-modulating biologics. Comparable as a US-listed small-cap biotech pursuing conditional activation of immune pathways in solid tumors.
  • Apexigen Inc. Clinical-stage immuno-oncology biotech developing antibody combinations with checkpoint inhibitors (e.g., sotigalimab + nivolumab). Comparable as a smaller biotech pursuing IO-combination strategies in solid tumors.
  • BioAtla Inc. Clinical-stage oncology biotech developing Conditionally Active Biologics, including TME-modulating antibodies. Comparable as a smaller US-listed biotech developing novel biologic approaches to solid tumors.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Buzzard Pharmaceuticals AB social profiles

Digital presence

Buzzard Pharmaceuticals AB financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Buzzard Pharmaceuticals AB leadership team

Management profile

Number of profiles

Profiles7 records

Buzzard Pharmaceuticals AB funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Buzzard Pharmaceuticals AB M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Buzzard Pharmaceuticals AB

What does Buzzard Pharmaceuticals AB do?

Buzzard Pharmaceuticals AB is a clinical-stage biotech company developing Isunakinra (EBI-005), a proprietary next-generation IL-1 inhibitor designed to block both IL-1α and IL-1β with high potency (up to 20x IL-1Ra). The drug candidate is being evaluated in a Phase 1/2a clinical trial in solid tumors, including KRAS-mutated microsatellite stable colorectal cancer and a planned study in neoadjuvant triple-negative breast cancer, both as monotherapy and in combination with PD-1 checkpoint inhibitors.

Is Buzzard Pharmaceuticals AB a public or private company?

Buzzard Pharmaceuticals AB is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Buzzard Pharmaceuticals AB founded?

Buzzard Pharmaceuticals AB was founded in 2016. It employs 1 to 10 people.

Where is Buzzard Pharmaceuticals AB based?

Buzzard Pharmaceuticals AB is headquartered in Solna, Sweden, in the Europe region.

How does Buzzard Pharmaceuticals AB make money?

One revenue line is on record: pharmaceutical Development.

Who are Buzzard Pharmaceuticals AB's main competitors?

Broad incumbents on record are Innate Pharma SA, Novartis AG, Swedish Orphan Biovitrum (Sobi) and Regeneron Pharmaceuticals. Direct peers are Cantargia AB and XBiotech Inc.. Emerging players are Compugen Ltd., Werewolf Therapeutics, Apexigen Inc. and BioAtla Inc..

Does Buzzard Pharmaceuticals AB have an API?

No public API is recorded for Buzzard Pharmaceuticals AB.

What industry is Buzzard Pharmaceuticals AB in?

Buzzard Pharmaceuticals AB's product category is Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales